Wie hoch ist der Preis für GBS Inc. (GBS)

Preis für GBS Inc. (GBS) ist $0.4732

Wie hoch ist die Marktkapitalisierung für GBS Inc. (GBS)

Marktkapitalisierung für GBS Inc. (GBS) ist $7.05M

GBS Inc. (GBS) Aktiensplits

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
Abbott Laboratories ABT.US	9	x285	US
Stryker Corporation SYK.US	9	x162	US
Medtronic plc MDT.US	7	x127	IE
Boston Scientific Corporation BSX.US	2	x4	US
Edwards Lifesciences Corporation EW.US	3	x12	US

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land